Terms: = Ovarian cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Treatment
53 results:
1. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
2. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract] [Full Text] [Related]
3. A 16-year bicentric retrospective analysis of ovarian tissue cryopreservation in pediatric units: indications, results, and outcome.
Grellet-Grün M; Delepine B; Le Van Quyen P; Avérous G; Durlach A; Greze C; Ladureau-Fritsch L; Lichtblau I; Canepa AS; Liné A; Paillard C; Pluchart C; Pirrello O; Rongieres C; Harika G; Becmeur F; Teletin M
Front Endocrinol (Lausanne); 2023; 14():1158405. PubMed ID: 37720539
[TBL] [Abstract] [Full Text] [Related]
4. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract] [Full Text] [Related]
5. Cost-effectiveness of Myomectomy versus Hysterectomy in Women with Uterine Fibroids.
Thao V; Moriarty JP; Stewart EA; Borah BJ
J Minim Invasive Gynecol; 2023 Oct; 30(10):813-819. PubMed ID: 37286130
[TBL] [Abstract] [Full Text] [Related]
6. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
[TBL] [Abstract] [Full Text] [Related]
7. Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study.
Yagi K; Maruo A; Ishida S; Aizawa F; Ushio S; Sakaguchi S; Kajizono M; Niimura T; Goda M; Hamano H; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Clin Exp Med; 2023 Oct; 23(6):2799-2804. PubMed ID: 36738305
[TBL] [Abstract] [Full Text] [Related]
8. Nanocurcumin preserves kidney function and haematology parameters in DMBA-induced ovarian cancer treated with cisplatin via its antioxidative and anti-inflammatory effect in rats.
Louisa M; Wanafri E; Arozal W; Sandhiutami NMD; Basalamah AM
Pharm Biol; 2023 Dec; 61(1):298-305. PubMed ID: 36708211
[TBL] [Abstract] [Full Text] [Related]
9. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract] [Full Text] [Related]
10. Frequency of thoracic recurrence based on pathological features in patients with ovarian epithelial tumors in stage I versus higher stages.
Matsutani H; Nakai G; Fujiwara S; Takahashi S; Yamamoto K; Ohmichi M; Osuga K
Jpn J Radiol; 2023 May; 41(5):500-509. PubMed ID: 36575285
[TBL] [Abstract] [Full Text] [Related]
11. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C
Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694
[TBL] [Abstract] [Full Text] [Related]
12. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.
van der Ploeg P; Uittenboogaard A; Thijs AMJ; Westgeest HM; Boere IA; Lambrechts S; van de Stolpe A; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2021 Nov; 163(2):433-444. PubMed ID: 34253390
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of survival outcomes and effects of therapy between subtypes of high-grade endometrial cancer - a population-based study.
Scharl S; Gerken M; Sprötge T; Kronberger K; Scharl A; Ignatov A; Ortmann O; Kölbl O; Klinkhammer-Schalke M; Papathemelis T
Acta Oncol; 2021 Jul; 60(7):897-903. PubMed ID: 33905297
[TBL] [Abstract] [Full Text] [Related]
14. The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Sep; 15(9):2491-2503. PubMed ID: 33690968
[TBL] [Abstract] [Full Text] [Related]
15. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract] [Full Text] [Related]
16. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
Rocconi RP; Grosen EA; Ghamande SA; Chan JK; Barve MA; Oh J; Tewari D; Morris PC; Stevens EE; Bottsford-Miller JN; Tang M; Aaron P; Stanbery L; Horvath S; Wallraven G; Bognar E; Manning L; Nemunaitis J; Shanahan D; Slomovitz BM; Herzog TJ; Monk BJ; Coleman RL
Lancet Oncol; 2020 Dec; 21(12):1661-1672. PubMed ID: 33271095
[TBL] [Abstract] [Full Text] [Related]
17. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract] [Full Text] [Related]
18. Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer.
Frey MK; Ellis AE; Zeligs K; Chapman-Davis E; Thomas C; Christos PJ; Kolev V; Prasad-Hayes M; Cohen S; Holcomb K; Blank SV
Am J Obstet Gynecol; 2020 Nov; 223(5):725.e1-725.e9. PubMed ID: 32598911
[TBL] [Abstract] [Full Text] [Related]
19. An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibody-Based Therapeutics in Overcoming Chemoresistance.
Kletzmayr A; Clement Frey F; Zimmermann M; Eberli D; Millan C
Biotechnol J; 2020 May; 15(5):e1900439. PubMed ID: 32028540
[TBL] [Abstract] [Full Text] [Related]
20. Differentiation between benign and malignant ovarian masses using multiparametric MRI.
Türkoğlu S; Kayan M
Diagn Interv Imaging; 2020 Mar; 101(3):147-155. PubMed ID: 31987805
[TBL] [Abstract] [Full Text] [Related]
[Next]
